Table 2 Toxicities and side effects of concurrent radiotherapy for locally advanced rectal cancer
Toxic reaction | Grade 1–2 | P | Grade 3 | P | ||
|---|---|---|---|---|---|---|
CAPE-OX-CRT group (%) | Control group (%) | CAPE-OX-CRT group (%) | Control group (%) | |||
Diarrhea | 14/30 (46.67%) | 5/26 (19.23%) | 0.028 | 5/30 (16.67%) | 5/26 (19.23%) | 0.431 |
Radiation dermatitis | 15/30 (50%) | 12/26 (46.15%) | 0.774 | 3/30 (10%) | 12/26 (46.15%) | 1.000 |
Bone-marrow suppression | 23/30 (76.67%) | 10/26 (38.46%) | 0.003 | 3/30 (10%) | 10/26 (38.46%) | 0.693 |
Nausea or vomiting | 18/30 (60%) | 7/26 (26.92%) | 0.012 | 1/30 (3.85%) | 7/26 (26.92%) | 1.000 |
Liver dysfunction | 9/30 (30%) | 2/26 (7.70%) | 0.047 | 0 | 2/26 (7.70%) | – |
Peripheral neurotoxic reactions | 6/30 (20%) | 1/26 (3.85%) | 0.108 | 0 | 1/26 (3.85%) | – |
Hand-foot syndrome | 1/30 (3.85%) | 0 | 1.000 | 1/30 (3.85%) | 0 | 1.000 |
Fatigue | 14/30 (46.67%) | 5/26 (19.23%) | 0.028 | 0 | 5/26 (19.23%) | – |